Intracellular accumulation of toxic turn amyloid-β is associated with endoplasmic reticulum stress in Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 1, 2013, Pages 11-20

  Soejima, Naoko ^a   Ohyagi, Yasumasa ^a   Nakamura, Norimichi ^a   Himeno, Eri ^a   Iinuma, Kyoko M ^a   Sakae, Nobutaka ^a   Yamasaki, Ryo ^a   Tabira, Takeshi ^b   Murakami, Kazuma ^c   Irie, Kazuhiro ^c   Kinoshita, Noriaki ^d   LaFerla, Frank M ^e   Kiyohara, Yutaka ^a   Iwaki, Toru ^a   Kira, Jun ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d Immuno Biological Laboratories Co Ltd   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid protein; Endoplasmic reticulum stress; GRP78; Oligomers; Presenilin 1; Rab protein; Toxic turn

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOSE REGULATED PROTEIN 78; PRESENILIN 1; PROTEIN; RAB 6 PROTEIN; RAB PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PSEN1 PROTEIN, HUMAN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR WEIGHT; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; BRAIN; CELL CULTURE; GENETICS; INTRACELLULAR FLUID; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELLS, CULTURED; ENDOPLASMIC RETICULUM STRESS; GTP-BINDING PROTEINS; HUMANS; INTRACELLULAR FLUID; MICE; MICE, TRANSGENIC; PRESENILIN-1; TAU PROTEINS; TRANSFECTION;

EID: 84881426112     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720513804871372     Document Type: Article

References (42)

1. Finder VH. Alzheimer's disease: A general introduction and path-omechanism. J Alzheimers Dis 22 (3): 5-19 (2010).
2. Golde TE, Dickson D, Hutton M. Filling the gaps in the Ap cas-cade hypothesis of Alzheimer's disease. Curr Alzheimer Res 3: 421-430 (2006).
3. Sakono M, Zako T. Amyloid oligomers: Formation and toxicity of AP oligomers. FEBS J 277: 1348-1358 (2010).
4. Ohyagi Y. Intracellular amyloid P-protein as a therapeutic target for treating Alzheimer's disease. Curr Alzheimer Res 5: 555-561 (2008).
5. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, et al. Intraneuronal amyloid p oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89: 1031-1042 (2011).
6. Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine treatment for Alzheimer mice promoting amy-loid-p degradation. Ann Neurol 69: 248-256 (2011).
7. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, et al. Oligomerization of Alzheimer's P-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24: 3592-3599 (2004).
8. Kokubo H, Kayed R, Glabe CG, Yamaguchi H. Soluble Ap oli-gomers ultrastructually localized to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res 1031: 222-228 (2005).
9. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dy-namic relationship between intracellular and extracellular pools of Ap. Am J Pathol 168: 184-194 (2006).
10. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-P in Alzheimer's disease. Nat Rev Neurosci 8: 499-509 (2007).
11. Masuda Y, Uemura S, Ohashi R, Nakanishi A, Takegoshi K, Shi-mizu T, et al. Identification of physiological and toxic conformations in AP42 aggregates. Chembiochem 10: 287-295 (2009).
12. Murakami K, Horikoshi-Sakuraba Y, Murata N, Noda Y, Masuda Y, Kinoshita N, et al. Monoclonal antibody against the turn of the 42-residue amyloid P-protein at positions 22 and 23. ACS Chem Neurosci 1: 747-756 (2010).
13. Miyoshi K, Ohyagi Y, Sakae N, Motomura K, Ma L, Taniwaki T, Furuya H, et al. Enhancement of activation of caspases by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J Alzheimers Dis 16: 551-564 (2009).
14. Ma L, Ohyagi Y, Miyoshi K, Sakae N, Motomura K, Taniwaki T, et al. Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J Alzheimers Dis 16: 565-575 (2009).
15. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Ap and synaptic dysfunction. Neuron 39: 409-421 (2003).
16. Hoozemans JJM, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 110: 165-172 (2005).
17. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid P deposition in sporadic Alzheimer's disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am J Pathol 157: 277-286 (2000).
18. Scheper W, Hoozemans JJM, Hoogenraad CC, Rozemuller AJ, Elkelenboom P, Baas F. Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. Neuropathol Appl Neurobiol 33: 523-532 (2007).
19. Takeda K, Araki W, Tabira T. Enhanced generation of intracellular AP42 amyloid peptide by mutation of presenilins PS1 and PS2. Eur J Neurosci 19: 258-264 (2004).
20. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. Neurology 75: 764-770 (2010).
21. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a genetic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18 (2007).
22. Toy-Miou-Leong M, Bachelet C-M, Pelaprat D, Restene W, For-gez P. NT agonist regulates expression of nuclear high-affinity neurotensin receptors. J Histochem Cytochem 52: 335-345 (2004).
23. Ohyagi Y, Tsuruta Y, Motomura K, Miyoshi K, Kikuchi H, Iwaki T, et al. Intraneuronal amyloid P42 enhanced by heating but counteracted by formic acid. J Neurosci Methods 159: 134-138 (2007).
24. Ma L, Ohyagi Y, Nakamura N, Iinuma KM, Miyoshi K, Himeno E, et al. Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine. J Alzheimers Dis 27: 225-237 (2011).
25. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 581: 3641-3651 (2007).
26. Zerial M, McBride. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2: 107-117 (2001).
27. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, et al. Intracellular Ap42 activates p53 promoter: A pathway to neurodegeneration in Alzheimer's disease. FASEB J 19: 255-257 (2005).
28. Ohyagi Y, Tabira T. Intracellular amyloid P-protein and its associated molecules in the pathogenesis of Alzheimer's disease. Mini Rev Med Chem 6: 1075-1080 (2006).
29. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, et al. Intraneuronal APP, not free Ap peptides in 3xTg-AD mice: Implications for tau versus Ap-mediated Alzheimer neurodegeneration. J Neurosci 31: 7691-7699 (2011).
30. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal AP causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45: 675-688 (2005).
31. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19: 363-372 (2010).
32. Camandola S, Mattson MP. Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim Biophys Acta 1813: 965-973 (2011).
33. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 (Suppl 2): 265-279 (2010).
34. Larson ME, Lesne SE. Soluble Ap oligomer production and toxicity. J Neurochem 120 (Suppl 1): 125-139 (2012).
35. Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular P-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Ap production. J Biol Chem 278: 31261-31268 (2003).
36. Arriagada C, Astorga C, Atwater I, Rojas E, Mears D, Caviedes R, et al. Endosomal abnormalities related to amyloid precursor protein in cholesterol treated cerebral cortex neuronal cells derived from trisomy 16 mice, an animal model of Down syndrome. Neurosci Lett 423: 172-177 (2007).
37. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28: 67-78 (2004).
38. Hoozemans JJM, Van Haastert ES, Nijholt DAT, Rozemuller AJM, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 174: 1241-1251 (2009).
39. Kudo T, Okumura M, Imaizumi K, Araki W, Morihara T, Tanimu-kai H, et al. Altered localization of amyloid precursor protein under endoplasmic reticulum stress. Biochem Biophys Res Commun 344: 525-530 (2006).
40. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer's disease: A novel neuronal trigger for inflammation and Alzheimer's pathology. J Neuroinflammation 6: 41 (2009).
41. Lindholm D, Wootz H, Korhonnen L. ER stress and neurodegenerative diseases. Cell Death Differ 13: 385-392 (2006).
42. Murakami K, Irie K, Ohigashi H, Hara H, Nagao M, Shimizu T, et al. Formation and stabilization model of the 42-mer Ap radical: Implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc 127: 15168-15174 (2005).